Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update
These results underscore the long-term clinical benefit of combining anti-PD-1 with ATRA, with survival rates comparable to anti-PD-1/combinations but with lower toxicity.
Authors
- Enrique Davilla
- Jessica S.W. Borgers (ORCID: https://orcid.org/0000-0002-6478-7821)
- Theresa Michelle Medina (ORCID: https://orcid.org/0000-0003-0579-4121)
- Elizabeth N. Katsnelson (ORCID: https://orcid.org/0000-0001-7987-3768)
- William Allen Robinson (ORCID: https://orcid.org/0000-0003-1875-9691)
- Kasey L. Couts (ORCID: https://orcid.org/0000-0002-2088-2229)
- Sapna Pradyuman Patel (ORCID: https://orcid.org/0000-0003-1339-1517)
- Richard P. Tobin (ORCID: https://orcid.org/0000-0003-3890-4534)
- Martin D. McCarter (ORCID: https://orcid.org/0000-0001-8174-1713)
- Dexiang Gao (ORCID: https://orcid.org/0000-0003-3920-7060)
- Claire M. Muckle
Institutions
- University of Colorado Cancer Center (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251349321
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Merck
- Cancer Center, University of Colorado